本帖最后由 老马 于 2013-3-13 13:43 编辑
! v. a9 q9 z! G5 ^2 t: g6 O2 P K: |
健择(吉西他滨)+顺铂+阿瓦斯汀. Q% O2 H$ e8 w s7 p1 E2 V0 u
Gemzar +Cisplatin + Avastin
/ s6 e4 M* ]2 |! Z: K( D) w Fhttp://annonc.oxfordjournals.org/content/21/9/1804.full
2 P: F6 A) o1 G l; A+ O( vOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ( L$ l8 l4 @) ]8 R; Z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ X+ l% u @8 o$ B" q, C( RResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 V$ L; Z) O5 p& c; L l
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 835)
6 a. b. r( P5 J0 d0 p0 _5 Y9 F+ M2 N
华为网盘附件:. X2 K N. k5 C7 r& J4 @
【华为网盘】ava.JPG" w3 z8 f6 p n; T- `# z d$ p' [) F2 l
|